The frequently studied polysaccharide, chitosan oligosaccharide/chitooligosaccharide
(COS) is the major degradation product of chitosan/chitin via chemical hydrolysis or …

Highlights•Antibody–drug conjugates represent an exciting new class of cancer
therapeutics.•ADCs comprise monoclonal antibodies that selectively deliver potent cytotoxic …

Chemotherapy is one of the major therapeutic options for cancer treatment. Chemotherapy
is often associated with a low therapeutic window due to its poor specificity towards tumor …

The marine habitat has produced a significant number of very potent marine-derived agents
that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of …

The potential of the marine environment to produce candidate compounds (structures) as
leads to, or even direct drugs from, has been actively discussed for the last 50 or so years …

At the time of the first issue of the Journal of Controlled Release (JCR), polymeric drugs,
polymer–drug and protein conjugates and block copolymer micelles carrying bound drugs …

Antibody–drug conjugates (ADCs) are monoclonal antibodies with covalently bound
cytotoxic drugs. They are designed to target tumor antigens selectively and offer the hope of …

Antibodies are potent components of the immune repertoire and have been successfully
exploited to treat bacterial infections. Recently an antibody–antibiotic conjugate (AAC) that …

Biological therapies play an increasing role in cancer treatment, although the number of
naked antibodies showing clinical efficacy as single agent remains limited. One way to …

Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an
increasingly important component of therapeutic regimens in oncology. The success of …